首页> 外文期刊>Kidney and blood pressure research >Renoprotective Effects of Various Angiotensin II Receptor Blockers in Patients with Early-Stage Diabetic Nephropathy.
【24h】

Renoprotective Effects of Various Angiotensin II Receptor Blockers in Patients with Early-Stage Diabetic Nephropathy.

机译:各种血管紧张素II受体阻滞剂对早期糖尿病肾病患者的肾脏保护作用。

获取原文
获取原文并翻译 | 示例
           

摘要

Background: There is increasing evidence that inhibition of the renin-angiotensin system provides renoprotection independent of blood pressure lowering. The aim of the present study was to determine whether various angiotensin II receptor blockers (ARBs) affect urinary albumin excretion (UAE), urinary liver-type fatty acid-binding protein (L-FABP) and 8-hydroxy-2'-deoxyguanosine (8-OHdG) levels in early-stage diabetic nephropathy patients with microalbuminuria. Methods: Sixty-eight diabetic nephropathy patients with microalbuminuria were randomly allocated to 1 of 4 treatment groups: losartan 100 mg/day (group A), candesartan 12 mg/day (group B), olmesartan 40 mg/day (group C), or telmisartan 80 mg/day (group D). Treatment was continued for 12 months. UAE, L-FABP and 8-OHdG excretion, serum creatinine, and 24-hour creatinine clearance (Ccr) were measured. Results: The serum creatinine and 24-hour Ccr were not affected during the experimental period in any of the groups. Systolic and diastolic blood pressures, UAE, urinary L-FABP and 8-OHdG excretion were significantly reduced after 6 and 12 months compared with baseline in any of the groups. DeltaL-FABP and Delta8-OHdG were significantly greater in group D than in the other 3 groups after 12 months. Conclusions: ARBs have renoprotection and this effect of telmisartan appears to be more potent than that of losartan, candesartan, or olmesartan in early-stage diabetic nephropathy patients.
机译:背景:越来越多的证据表明,抑制肾素-血管紧张素系统可提供肾脏保护,而与降低血压无关。本研究的目的是确定各种血管紧张素II受体阻滞剂(ARB)是否会影响尿白蛋白排泄(UAE),尿肝型脂肪酸结合蛋白(L-FABP)和8-羟基-2'-脱氧鸟苷(早期糖尿病性肾病合并微量白蛋白尿的患者的8-OHdG)水平。方法:将68例微蛋白尿尿症的糖尿病肾病患者随机分配至4个治疗组中的1个:氯沙坦100毫克/天(A组),坎地沙坦12毫克/天(B组),奥美沙坦40毫克/天(C组),或替米沙坦80毫克/天(D组)。治疗持续了12个月。测量了阿拉伯联合酋长国,L-FABP和8-OHdG排泄,血清肌酐和24小时肌酐清除率(Ccr)。结果:任何一组实验期间,血清肌酐和24小时Ccr均未受影响。与任何组相比,在6个月和12个月后,收缩压和舒张压,UAE,尿L-FABP和8-OHdG排泄量均显着降低。 12个月后,D组的DeltaL-FABP和Delta8-OHdG显着高于其他3组。结论:ARB具有肾脏保护作用,在早期糖尿病肾病患者中,替米沙坦的这种作用似乎比氯沙坦,坎地沙坦或奥美沙坦更有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号